Gilead Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gilead Sciences (GILD).

Price Target Range — 9 Quarters

Analyst Consensus — 22 Analysts

18Buy

4Hold

Consensus RatingBuy# Analysts22Avg. Consensus PT$151Upside to Avg. PT-9.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	UBS	Michael Yee	PT Raise	Buy	$175→$195
Oct 30, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$170→$190
Oct 30, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$165→$188
Oct 30, 2026	Scotiabank	Louis Chen	PT Raise	Sector Outperform	$177→$200
Oct 30, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$160→$175
Oct 30, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$163→$183
Oct 30, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$165→$190
Oct 30, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$158→$181
Oct 30, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$126→$131
Oct 30, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$155→$175
Oct 30, 2026	Needham	Joseph Stringer	PT Raise	Buy	$170→$200
Oct 20, 2026	B of A Securities	Tim Anderson	PT Raise	Buy	$168→$172
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$123→$126
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$150→$158
Oct 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$160→$170
Oct 7, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$165→$163
Sep 10, 2026	HSBC	Morten Herholdt	PT Raise	Buy	$155→$175
Aug 5, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$120→$123
Aug 5, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $170 to $190.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $160 to $175.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $163 to $183.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $165 to $190.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $158 to $181.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $126 to $131.

Benzinga Newsdesk

Gilead Sciences Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Gilead Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PRO
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

People Also Watch

People Also Watch

Gilead Sciences Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Gilead Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PROTD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PROMorgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PROWells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PROTruist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRORBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PRO
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131